CYFRA-21-1 QUANTITY MEASUREMENT IN THE URINE OF PATIENTS WITH CARCINOMA OF THE URINARY-BLADDER AND TRACT

CYFRA 21-1 (Cytokeratin 19 fragment) has been shown to be a useful ser ological tumour marker in invasive forms of the urinary bladder cancer (1). For CYFRA 21-1 a cut-off value of 2.6 ng/mL has been chosen base d on 95% specificity with regard to benign urological diseases. The se nsitivity has been shown to be superior to that of TPA (tissue polypep tide antigen) or TPS (tissue polypeptide specific antigen). The aim of this study was to find out, firstly, preanalytical conditions of CYFR A 21-1 measurement in the urine and, secondly, the possible clinical v alue of CYFRA 21-1 in the urine of patients with cancer of the urinary bladder and tract.